( S ) Few studies of medical therapies for endometriosis report outcomes that are relevant to patients , and many women gain only limited or intermittent benefit from treatment
OBJECTIVE To assess patient response rates to medical therapies used to treat endometriosis-associated pain .
Efficacy and safety of nafarelin in the treatment of endometriosis.
The efficacy and safety of the gonadotropin-releasing hormone agonist nafarelin for treatment of endometriosis were compared with those of danazol in two large-scale , double-blind trials . Assessment s of severity of symptoms , laparoscopic scores before and after therapy , and pregnancy rates showed that nafarelin , 400 and 800 micrograms administered intranasally , was as efficacious as oral danazol , 600 and 800 mg . The adverse effects seen with nafarelin , mainly hot flashes , were related to its mode of action , namely hypoestrogenemia induced by reversible inhibition of ovarian hormone production . Hypoestrogenemia was associated with a decrease of bone density in the lumbar vertebrae , but these changes were partially or completely reversible after treatment was discontinued . No significant changes in bone mass occurred in the distal radius . Danazol was associated with and rogenic and metabolic adverse effects , including weight gain , negative effects on the lipid profile , and elevated liver enzyme levels .  Nafarelin was found to be as effective as danazol for the management of endometriosis , with a different and more favorable safety profile
( S ) Few studies of medical therapies for endometriosis report outcomes that are relevant to patients , and many women gain only limited or intermittent benefit from treatment
OBJECTIVE To assess patient response rates to medical therapies used to treat endometriosis-associated pain .